Explore

Trendline Trendline
Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease

Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease

Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease
Trendline Trendline
Epirium Bio Presents New Data on 15-PGDH Inhibitor for Inflammatory Bowel Disease

Epirium Bio Presents New Data on 15-PGDH Inhibitor for Inflammatory Bowel Disease

Epirium Bio Presents New Data on 15-PGDH Inhibitor for Inflammatory Bowel Disease
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
SKYRIZI® Gains Approval for Ulcerative Colitis Treatment in Ontario and Alberta

SKYRIZI® Gains Approval for Ulcerative Colitis Treatment in Ontario and Alberta

SKYRIZI® Gains Approval for Ulcerative Colitis Treatment in Ontario and Alberta
Trendline Trendline
Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks
Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies